Stramsen Biotech key facts
as of Oct 2026- Developer of plant-based medicines intended to treat a wide range of infectious and noninfectious diseases.
- Stramsen Biotech is valued at approximately $807.0M as of Oct 2026 (last reported valuation).
- It has raised $35.0M; the latest was Later Stage VC ($25.0M) in Apr 2025.
- Notable investors include Global Emerging Markets.
- Stramsen Biotech has filed 1 Form D with the SEC, most recently May 2024 ( sold).
- Status: Privately Held (backing).
Stramsen Biotech's last reported valuation, Oct 2023. Nothing priced has surfaced since.
- ·Watch Stramsen Biotech: the Monday email on marks, rounds and moves
Stramsen Biotech funding rounds
No funding rounds for Stramsen Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Stramsen Biotech
1Stramsen Biotech valuation
Stramsen Biotech's last reported valuation was $807 million in Oct 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Stramsen Biotech raised?
Stramsen Biotech has filed 1 Form D with the SEC, most recently in May 2024 (null sold).
Stramsen Biotech investors
1 investor is on record for Stramsen Biotech, including Global Emerging Markets. By type, the record holds 1 private equity firm.
About Stramsen Biotech
Developer of plant-based medicines intended to treat a wide range of infectious and noninfectious diseases. The company's platform leverages an extensive medicinal plant database to develop innovative treatments with improved safety profiles and reduced side effects, enabling the global healthcare market to access more effective, natural, and sustainable drugs for conditions such as cancer, cardiovascular diseases, diabetes, HIV, and more.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2020
- Website
- stramsenbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.